Expert Interviews

Sharon Fekrat, MD, FACS, FASRS, reviews the science behind dopamine signaling in the retina and its potential role in the progression of age-related macular degeneration.

Dimitra Skondra, MD, PhD, FASRS, shares her perspective on the evolving treatment landscape for dry age-related macular degeneration and the key questions facing the field.

Carl D. Regillo, MD, FACS, reviews long-term efficacy and safety findings from the Port Delivery System clinical trial program.

Michael Singer, MD, discusses the role of steroids, biomarkers, and second-generation therapies in diabetic macular edema management.

In this interview from the 2026 Retina World Congress, Katherine Talcott, MD underscores that retinal vein occlusions (RVOs) should prompt retina specialists to look beyond the eye and ensure patients are connected to primary care and cardiology. She highlights the importance of systemic risk factor management and interdisciplinary coordination as essential components of comprehensive RVO care.

Ashkan Abbey, MD, reviews findings from the DAVIO2 and VERONA clinical trials for the bioerodible intravitreal insert.

Patricio G. Schlottmann, MD, examines why injection frequency drives treatment failure in wet AMD and the particular challenges facing patients in Latin America.

Posture, operating room setup, and small workflow adjustments can reduce cumulative neck and back strain over time.

Jay Chhablani, MD, on multimodal imaging, OCT biomarkers, and the importance of early diagnosis as treatment options emerge

Hannah Chiu, MD, FRCSC, highlights some of the early benefits of an AI-operated telephone call system for postoperative patient care.

Stephanie Marioneaux, MD, gives insight into the inspiration and research discussed in her talk “First in Medicine: An African American perspective from 1700 to 1940" as the Patricia Bath Distinguished Lecture at the National Medical Association's annual conference in New York City, NY.

M. Roy Wilson, MD, touches upon reconceptualizing the use of race in medicine as part of his Robert Copeland Distinguished Lecture at the National Medical Association's annual conference in New York City, NY.

Scott Walter, MD, an investigator in the TENAYA and LUCERNE trials discusses the year 2 data for the treat-and-extend regimen of faricimab for the treatment of nAMD and DME.

Carl Danzig, MD, points out that the sooner patients can be diagnosed, the sooner ophthalmologists can treat them and preserve their vision.

Tom Ruggia, President and CEO of Samsara Vision, provides updates on the lead asset for late-state age-related macular degeneration: Smaller-incision, new generation, implantable miniature telescope (SING IMT).

At AAO 2022, Justis Ehlers, MD, presented a talk entitled, "Defining the Fluid Problem in Neovascular AMD: To Dry or Not to Dry?"

Roger A. Goldberg, MD, MBA, discusses his 2022 AAO poster: "T&E-Based Personalized Treatment Interval Dynamics in the YOSEMITE/RHINE Trials of Faricimab in DME."

Tunde Peto, MD, PhD, shares some ophthalmic initiatives she's excited about in light of EURETINA 2022.

Tunde Peto, MD, PhD, discussed two of her presentations at EURETINA 2022: "UK Biobank retinal imaging grading: methodology, baseline characteristics and findings for common ocular diseases" and "Retinal phenotyping of different variants of Alzheimer’s disease using ultra-widefield imaging."

Dara Conlon, Executive Vice President of EURETINA, and Prof. Anat Loewenstein, General Secretary of EURETINA, discuss some key features of this year's Congress.

Nancy Lurker, CEO of EyePoint Pharmaceuticals, shares the 12-month safety data from the DAVIO trial, investigating EYP-1901 for the treatment of wet age-related macular degeneration (AMD) and nonproliferative diabetic retinopathy.

Victor Gonzalez, MD, shares updates from the Phase 4 Paladin study regarding the safety and efficacy of fluocinolone in diabetic macular edema.

Claire Gelfman, PhD, Chief Scientific Officer of Foundation Fighting Blindness, supplies a brief overview of the foundation's aims and updates on retinal disease research.

At ASRS 2022, John Kitchens, MD, presented, “Personalized Treatment Interval Dosing Dynamics Over 2 Years in the Phase 3 YOSEMITE and RHINE Trials of Faricimab."

Kerrie Brady, CEO of OcuTerra Therapeutics, shares an update on their eye drop-based integrin inhibitor, which is intended to be a novel therapy for diabetic retinopathy.

At ASRS 2022, Sunir Garg, MD, FACS, discussed his talk entitled, “Impact of Delay in Repair of Rhegmatogenous Retinal Detachment: Real-World Outcomes from the IRIS Registry.”

At ASRS 2022, Sally Ong, MD, presented a talk entitled, “Vitrectomy vs Vitrectomy With Scleral Buckling in the Treatment of Giant Retinal Tear Related Retinal Detachments: International Multicenter Study.” Here she shares the biggest takeaways.

Rahul Khurana, MD, discusses his 2022 ASRS talk, “Phase 2 Study of THR-149, a Plasma Kallikrein Inhibitor in Patients With DME Who Respond Suboptimally to Anti-VEGF Treatment (Month 6 Results of Part A of the KALAHARI Study),” which he presented in New York City, New York.